Amylyx Pharmaceuticals, Inc. AMLX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s total equity?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported total equity of $273.16M in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s total equity changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s total equity increased by 35.6% year-over-year, from $201.42M to $273.16M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s total equity?
- Over 5 years (2020 to 2025), Amylyx Pharmaceuticals, Inc.'s total equity has grown at a 35.5% compound annual growth rate (CAGR), from -$66.73M to $305.26M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.